Silo pharma inc SILO.US 總覽分析
SILO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
SILO 近期報酬表現
-3.85%
Silo pharma inc
3.56%
同產業平均
1.47%
S&P500
與 SILO 同產業的標的表現
- AMIX Autonomix medical inc價值 -趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
SILO 公司資訊
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. It is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. Its lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis.